BCM
MPLT

Bridgeway Capital Management’s MapLight Therapeutics MPLT Stock Holding History

Bridgeway Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
+35,000
New +$1.01M 0.02% 691

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's MPLT Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 35,000 shares worth $1.25M. The stake represents 0.02% of the portfolio and ranks #691 among its holdings.

100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Bridgeway Capital Management held 35,000 shares of MapLight Therapeutics worth $1.25M as of Q2 2026.
  • MapLight Therapeutics was a new Bridgeway Capital Management position in Q2 2026.
  • MapLight Therapeutics made up 0.02% of Bridgeway Capital Management's portfolio in Q2 2026, its #691 holding.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.